FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)

Kim Boesen, Peter C Gøtzsche, John PA Ioannidis
doi: https://doi.org/10.1101/2020.01.22.20018499

Article Information

doi 
https://doi.org/10.1101/2020.01.22.20018499
History 
  • January 27, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Kim Boesen1,*,
  2. Peter C Gøtzsche2 and
  3. John PA Ioannidis3,4
  1. 1Nordic Cochrane Centre, Rigshospitalet, Dept. 7811, Copenhagen, Denmark
  2. 2Institute for Scientific Freedom, Denmark
  3. 3Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA
  4. 4Departments of Medicine, of Health Research and Policy, Biomedical Data Science, and Statistics, Stanford University, Stanford, CA, USA
  1. ↵*Corresponding author
    Kim Boesen, Nordic Cochrane Centre, Rigshospitalet, Dept. 7811, Blegdamsvej 9, 2100 Copenhagen Ø, +45 35457112, kb{at}cochrane.dk
Back to top
Posted January 27, 2020.
Download PDF
Data/Code
Email
FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)
Kim Boesen, Peter C Gøtzsche, John PA Ioannidis
medRxiv 2020.01.22.20018499; doi: https://doi.org/10.1101/2020.01.22.20018499
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area